SCHEMBL23927005

SCHEMBL23927005

Cc1ccc(Oc2ccc(-n3c(=O)[nH]c4cncnc43)cn2)cc1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
P2RX3 P56373 1/20 0.35
P2RX2 Q9UBL9 1/20 0.35
MMP13 P45452 3/20 0.35
CYP3A4 P08684 3/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP2C9 P11712 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
HSD17B10 Q99714 1/20 0.35
HRH3 Q9Y5N1 8/20 0.34
USP2 O75604 2/20 0.33
CYP1A2 P05177 2/20 0.33
DRD1 P21728 2/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
HRH1 P35367 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30078973 1.00 EGLN1 (0.38) EGLN1KDM4EPOLBP2RX3P2RX2
SCHEMBL25027663 0.88 GPR84 (0.38) EGLN1KDM4EP2RX3P2RX2CYP3A4
SCHEMBL30078913 0.87 DRD1 (0.40) KDM4EP2RX3P2RX2CYP3A4ALDH1A1
SCHEMBL23927041 0.87 DRD1 (0.40) KDM4EP2RX3P2RX2CYP3A4ALDH1A1
SCHEMBL30079298 0.86 KDM4E (0.38) EGLN1KDM4EPOLBMMP13HRH3
SCHEMBL23927056 0.86 KDM4E (0.38) EGLN1KDM4EPOLBMMP13HRH3
SCHEMBL30079057 0.84 TNKS (0.38) EGLN1KDM4EPOLBMMP13CYP3A4
SCHEMBL23926975 0.84 TNKS (0.38) EGLN1KDM4EPOLBMMP13CYP3A4
SCHEMBL23927021 0.84 POLB (0.35) POLBP2RX3P2RX2MMP13CYP3A4
SCHEMBL23927007 0.78 SLC22A12 (0.34) P2RX3P2RX2MMP13CYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US claimed
EP-4139306-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2023-03-01 EP claimed
CN-115380032-A KV3 enhancers for the treatment of cognitive disorders 豪夫迈·罗氏有限公司 2022-11-22 CN claimed
WO-2021214090-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2021-10-28 WO claimed
EP-3901152-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2021-10-27 EP claimed
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-4139306-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2023-03-01 EP disclosed
CN-115380032-A KV3 enhancers for the treatment of cognitive disorders 豪夫迈·罗氏有限公司 2022-11-22 CN disclosed
WO-2021214090-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2021-10-28 WO disclosed
EP-3901152-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed
EP-3901152-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS KCNN3, KCNA4, KCNA3 EGLN1 3599/4885KDM4E 200/4885POLB 3774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.